Insider Purchases: Inside the Buy
Tag: Pharma & Biotech
Director Purchases Shares of Johnson & Johnson
A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?
Tags:
blue-chip stocks,
Buy-JNJ,
buy-or-sell-jnj,
director-buying,
Dividend Stocks,
featured-insiders,
funanc1al edge,
funanc1al humor,
Funanc1al investing,
FUNstock Index,
Healthcare Stocks,
Insider Purchases,
JNJ,
Johnson & Johnson,
Long-Term Investing,
MedTech,
Pharma & Biotech,
risks-buying-jnj,
Value Investing,
why-buy-jnj
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.
